Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1
NCT07683000Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 3 trial of lenacapavir, Teropavimab, zinlirvimab in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Jul 2026; status: recruiting.
02
Drugs
lenacapavirTeropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07683000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683000.